Vaccines
GeoVax Advances Toward European Approval for Mpox Vaccine Following EMA Guidance
GeoVax Labs, Inc. has received positive Scientific Advice from the European Medicines Agency, paving the way for expedited approval of its GEO-MVA Mpox vaccine in the EU, potentially accelerating revenue generation.
Tonix Pharmaceuticals to Showcase TNX-801 Mpox Vaccine Data at Vaccine Congress 2025
Tonix Pharmaceuticals will present preclinical data on its TNX-801 mpox vaccine candidate at the Vaccine Congress 2025, highlighting its potential to address public health threats.
GeoVax Announces $6 Million Public Offering to Advance Immunotherapies and Vaccines
GeoVax Labs, Inc. secures approximately $6 million in a public offering to fund the development of its immunotherapies and vaccines against cancer and infectious diseases.
GeoVax Secures Patent for Innovative Malaria Vaccine Design
GeoVax Labs, Inc. has been granted a U.S. patent for a novel vaccine construct aimed at preventing malaria, marking a significant step forward in the fight against the disease and other infectious threats.
GeoVax's GEO-CM04S1 Shows Superior Immune Response in CLL Patients Compared to mRNA Vaccines
GeoVax Labs, Inc. reports that its GEO-CM04S1 vaccine has demonstrated superior T cell responses in chronic lymphocytic leukemia (CLL) patients compared to an authorized mRNA COVID-19 vaccine, highlighting potential advancements in protecting immunocompromised individuals.
GeoVax Gains EMA Support for Streamlined Mpox and Smallpox Vaccine Development
GeoVax Labs, Inc. receives favorable regulatory guidance from the European Medicines Agency, simplifying the development pathway for its GEO-MVA vaccine against Mpox and smallpox, marking a significant step towards addressing global vaccine shortages.
GeoVax to Showcase Innovative Vaccines and Therapies at BIO International Convention 2025
GeoVax Labs, Inc. announces its participation in the 2025 BIO International Convention, highlighting its pipeline of vaccines and immunotherapies for infectious diseases and cancer, underscoring the company's role in advancing global health solutions.
GeoVax to Showcase Positive Immune Response Data for GEO-CM04S1 in CLL Patients at EHA 2025 Congress
GeoVax Labs, Inc. will present clinical data at the European Hematology Association 2025 Congress, demonstrating the superior cellular immune response of its GEO-CM04S1 vaccine in chronic lymphocytic leukemia patients compared to mRNA-based vaccines.
GeoVax's Multi-Antigen COVID-19 Vaccine Shows Promise Against Variants
GeoVax Labs, Inc. reports preclinical success of its multi-antigen COVID-19 vaccines, GEO-CM04S1 and GEO-CM02, in providing durable, cross-reactive immunity against SARS-CoV-2 variants, including Omicron XBB.1.5, highlighting the potential for broader protection without the need for frequent updates.
GeoVax to Present COVID-19 Vaccine Breakthroughs at Keystone Symposia
GeoVax Labs, Inc. will showcase data from two key studies at the Keystone Symposia, highlighting the cross-reactivity and broad-spectrum immunity of its COVID-19 vaccine candidates, marking a significant step forward in the fight against evolving SARS-CoV-2 variants.
FDA Updates COVID-19 Vaccination Strategy, GeoVax Poised to Meet Targeted Needs
The FDA has shifted to a risk-based COVID-19 vaccination approach, prioritizing protection for vulnerable populations. GeoVax's multi-antigen vaccine GEO-CM04S1 appears well-positioned to address these evolving public health requirements.
GeoVax Develops Multi-Antigen COVID-19 Vaccine Targeting Immunocompromised Populations
GeoVax's innovative GEO-CM04S1 vaccine addresses critical gaps in COVID-19 immunization strategies by offering broad, durable protection for vulnerable populations as HHS shifts towards risk-based vaccine recommendations.
Medical Alliance Launches Campaign Challenging COVID-19 mRNA Vaccine Use in Children and Pregnant Women
The Independent Medical Alliance's 'Smart Moms Ask' campaign aims to halt mRNA COVID-19 vaccinations for children and pregnant women, citing potential health risks based on recent studies and data.
GeoVax Reveals Promising Dual-Action Vaccine with Potential COVID-19 and Mpox Protection
A novel vaccine candidate, GEO-CM04S1, demonstrates robust immunogenicity against both COVID-19 and Mpox in immunocompromised and healthy populations, offering potential breakthrough in infectious disease prevention.
GeoVax Advances COVID-19, Cancer, and Biosecurity Vaccine Platforms Despite BARDA Contract Setback
GeoVax Labs reports significant progress across multiple vaccine development programs, including a multi-antigen COVID-19 vaccine for immunocompromised patients, an oncology treatment for head and neck cancer, and a Mpox/smallpox vaccine addressing global biosecurity needs.
Tonix Pharmaceuticals Presents Promising Single-Dose Mpox Vaccine Candidate
Tonix Pharmaceuticals revealed preclinical data for TNX-801, a single-dose mpox vaccine that demonstrates durable protection in animals, including immunocompromised subjects. The vaccine could potentially address global health emergency challenges related to mpox outbreaks.
GeoVax Highlights Mpox Threat After North Carolina Wastewater Detection
Wastewater samples in North Carolina reveal the first state detection of Clade I Mpox, a more virulent strain with higher transmissibility. GeoVax responds by emphasizing the need for expanded vaccine preparedness and domestic manufacturing capabilities.
GeoVax Reveals Promising Multi-Antigen COVID-19 Vaccine with Strong Immunocompromised Patient Response
GeoVax's experimental COVID-19 vaccine GEO-CM04S1 demonstrates exceptional immune responses across diverse populations, particularly in immunocompromised patients, potentially offering a more robust alternative to existing vaccines.
Tonix Pharmaceuticals Reveals Promising Single-Dose Mpox Vaccine Data
Tonix Pharmaceuticals presented preclinical data on TNX-801, a single-dose mpox vaccine that demonstrates robust protection across animal models, potentially offering a significant breakthrough in combating global mpox outbreaks.
BioVaxys and SpayVac-for-Wildlife Expand License Agreement to Aquaculture Market
BioVaxys Technology Corp. and SpayVac-for-Wildlife have broadened their license agreement to include commercial aquaculture, potentially opening significant revenue opportunities in the global fish farming market through innovative fertility-control vaccine technology.
GeoVax Bolsters Technical Development with Experienced Biologics Executive
GeoVax Labs has appointed Dr. Senthil Ranganathan as Vice President of Technical Development and CMC Operations, signaling a strategic move to enhance the company's biologics development capabilities and advance its clinical-stage vaccine and immunotherapy portfolio.
GeoVax Embraces AI Integration in $500B Healthcare Initiative
GeoVax Labs announces comprehensive AI integration across its vaccine and immunotherapy programs as part of the Stargate Initiative, a $500 billion private-sector investment plan aimed at revolutionizing U.S. healthcare and biosecurity through advanced technologies.